RESULTS: BFE and Met improved diabetic parameters, mitigating hyperglycemia, dyslipidemia, and inflammation by lowering serum glucose, total cholesterol, triglycerides, very low-density lipoprotein, interleukin-6, adenosine deaminase activity, and reactive species levels, while restoring high-density lipoprotein and paraoxonase-1 activity in blood. The gene discussed is PON1; the disease is Hyperglycemia.